In patients SU360 (SF3B1 and KMT2D mutant secondary AML), SU484 (IDH1/FLT3-ITD/NPM1 mutant), and SU892 (RUNX1-mutant/FLT3-TKD), there were substantial epigenetic differences between diagnosis and relapse, along with significant heterogeneity within each timepoint (Figure 4c and d, Figure 4—figure supplement 1a). Here, RUNX1 is linked to acute myeloid leukemia.